Feb. 26, 2007 — Maquet Critical Care announced its has received FDA 510(k) clearance for its breakthrough NAVA (Neurally Adjusted Ventilatory Assist) technology for optional use with the company’s SERVO-i ventilator. The SERVO-i ventilator with NAVA option is intended for treatment and monitoring of all patients, neonatal, pediatric and adults who require mechanical ventilation.
The NAVA technology detects respirator signals sent from the brain to the diaphragm 9in cases where the brain-to-diaphragm electrical signal is intact) and transmits those signals to the SERVO-i ventilator. By enabling the respiratory signals from the patient’s brain to control ventilator function, NAVA technology results in unprecedented coordination between diaphragmatic activation and ventilatory support throughout the breathing cycle.
For more information visit www.maquet.com/us.